Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$63.07

0.25 (0.40%)

, LLY

Eli Lilly

$80.26

0.52 (0.65%)

04:55
10/02/16
10/02
04:55
10/02/16
04:55

European Academy of Dermatology & Venereology to hold conference

25th Annual EADV Congress is being held in Vienna, Austria on September 28-October 2.

ABBV

AbbVie

$63.07

0.25 (0.40%)

LLY

Eli Lilly

$80.26

0.52 (0.65%)

CELG

Celgene

$104.53

1.76 (1.71%)

CUTR

Cutera

$11.92

0.17 (1.45%)

CYNO

Cynosure

$50.94

0.33 (0.65%)

DAN

Dana Holding

$15.59

0.43 (2.84%)

MYL

Mylan

$38.12

-0.35 (-0.91%)

NVS

Novartis

$78.96

-0.29 (-0.37%)

PFE

Pfizer

$33.87

0.55 (1.65%)

PHG

Philips

$29.59

0.21 (0.71%)

REGN

Regeneron

$402.02

-4.34 (-1.07%)

RNR

RenaissanceRe

$120.16

-0.02 (-0.02%)

SNY

Sanofi

$38.19

0.36 (0.95%)

ZLTQ

ZELTIQ

$39.22

0.85 (2.22%)

  • 04

    Oct

  • 07

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 28

    Mar

  • 29

    Mar

ABBV AbbVie
$63.07

0.25 (0.40%)

07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
LLY Eli Lilly
$80.26

0.52 (0.65%)

09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
09/27/16
09/27/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Neutral at Goldman with analyst Jami Rubin saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. 2. AutoZone (AZO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying the company is at a positive inflection in 7 year and older vehicles, which is strongly correlated to same-store-sales. 3. Consolidated Edison (ED) upgraded to Hold from Sell at Evercore ISI with analyst Greg Gordon saying the joint settlement proposal filed in the CECONY rate case mitigates downside risk. 4. Crown Holdings (CCK) upgraded on multiple catalysts at BMO Capital with analyst Mark Wilde citing valuation, his belief that the company will resume returning cash to shareholders in 2017, and his belief that the company's results should be boosted by " a wave of domestic and offshore expansion projects." 5. Francesca's (FRAN) upgraded to Buy from Hold at Stifel with analyst Richard Jaffe saying the company's "appealing merchandise" makes it very likely that its sales will grow going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
JANY
09/21/16
DOWNGRADE
Target $36
JANY
Neutral
Janney downgrades Clovis with buyout speculation at 'fever pitch'
Janney Capital analyst Roy Buchanan downgraded Clovis Oncology (CLVS) to Neutral from Buy with an increased fair value estimate of $36. Clovis is up 17c to $35.00 in late morning trading. In a research note partially titled, "May Be Right, May Be Crazy - M&A Speculation At Fever Pitch," Buchanan says there is a "finite chance" that Clovis will need to market its PARP inhibitor rucaparib by itself. He believes a late-2016 approval for rucaparib is likely. The analyst attributes his increased fair value estimate to "acquisition optionality." Reports of Takeda's (TKPYY) reserving up to $15B for acquisitions and Medivation's (MDVN) takeout have given Clovis shares a lift, Buchanan tells investors. The analyst adds that rumors surfaced yesterday of potential interest in the company from Eli Lilly (LLY).
09/27/16
GSCO
09/27/16
UPGRADE
Target $95
GSCO
Buy
Eli Lilly upgraded to Buy from Neutral at Goldman
Goldman analyst Jami Rubin upgraded Eli Lilly to Buy and increased its price target to $95 from $89 saying the company is entering a long lasting period of accelerating topline and earnings growth driven by its late stage pipeline. Rubin projects $12.5B of new product sales by 2020 and double digit earnings growth over the next five years, even without Sola. The analyst sees a 35%, up from 25%, probability of success for Sola with a bull case scenario that can lead to almost $7.5B in peak sales and "super charge" earnings. Even without Sola, Rubin sees favorable risk/reward given durability of earnings and said it is the least exposed to above-CPI price increases.
CELG Celgene
$104.53

1.76 (1.71%)

09/12/16
PIPR
09/12/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer says Celgene GED-0301 data 'vague'
Piper Jaffray analyst Joshua Schimmer says he remains skeptical on the profile of Celgene's GED-0301 for Crohn's disease. This morning's "vague press release doesn't help despite the company's expressed confidence," Schimmer tells investors in a research note. He notes that while GED-0301 is not a relevant driver of his investment thesis, the drug is important to sentiment overall. The analyst reiterates an Overweight rating on Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/16/16
RBCM
09/16/16
NO CHANGE
RBCM
Celgene shares can advance, says RBC Capital
RBC Capital analyst Michael Yee says that Celgene's stock "can grind higher" as investors eventually understand that the company's GED-0301 drug could potentially generate $1B in revenue. Yee says endoscopy data the company is expected to present next month on GED-0301 "isn't likely to be impressive." However, he thinks the data will "suggest that the drug is working," and he says that investor expectations are low, while the recent pullback in the shares has created an attractive entry point.
CUTR Cutera
$11.92

0.17 (1.45%)

CYNO Cynosure
$50.94

0.33 (0.65%)

09/13/16
09/13/16
NO CHANGE

Cynosure poised to beat Street expectations, says Stifel
Stifel analyst Jonsthan Block says his firm's proprietary tracker shows that Cynosure's non-invasive body contouring device "has had significant traction." The analyst adds that Cynosure's results can beat expectations in 2017 and 2018 even if its "system momentum" in North America slows significantly. He reiterates a $62 price target and Buy rating on the shares
06/21/16
BMUR
06/21/16
NO CHANGE
Target $35
BMUR
Buy
ZELTIQ should remain dominant in its space, says Brean Capital
Brean Capital said they would be buyers of ZELTIQ (ZLTQ) as they expect the company to remain the dominant player in its space. The firm said competitors are far behind despite Cynosure's (CYNO) strong entry, which Brean Capital expects will temper as they fully tap into their installed base. Brean Capital reiterated its Buy rating and $35 price target on ZELTIQ shares.
04/27/16
BMUR
04/27/16
NO CHANGE
Target $54
BMUR
Buy
Cynosure price target raised to $54 from $46 at Brean Capital
Brean Capital raised its price target on Cynosure to $54 from $46 following another quarterly beat that included excellent top-line results in what is typically their slowest quarter. The firm sees the potential for upside, given that seasonality is on the company's side, and reiterated its Buy rating on Cynosure shares.
04/27/16
LEER
04/27/16
NO CHANGE
Target $60
LEER
Outperform
Cynosure price target raised to $60 from $53 at Leerink
Leerink analyst Richard Newitter raised his price target for Cynosure to $60 from $53 following a "solid" Q1 revenue and EPS beat. The analyst says he has confidence that key new product cycles will continue to build momentum, with potential to drive further upside. Over the long run, the company should be a prime beneficiary of rising global trends toward less invasive cosmetic procedures, Newitter tells investors in a research note. The analyst reiterates an Outperform rating on the shares.
DAN Dana Holding
$15.59

0.43 (2.84%)

09/16/16
LEHM
09/16/16
UPGRADE
Target $20
LEHM
Overweight
Dana Holding upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Brian Johnson upgraded Dana Holding to Overweight saying the company is "relatively better positioned within the group" given its exposure to light trucks, which the analyst believes is experiencing "robust demand." Johnson views Dana's investor day as near-term catalyst and upped his price target for the shares to $20 from $12.
MYL Mylan
$38.12

-0.35 (-0.91%)

09/30/16
LEER
09/30/16
NO CHANGE
Target $45
LEER
Outperform
Mylan price target cut to $45 on lower EpiPen estimates at Leerink
Leerink analyst Jason Gerberry lowered his EpiPen sales forecasts by 33-45% from 2017-2021 in light of recent company updates, including its plan to launch an authorized generic of the emergency treatment later this year. While Mylan "appears on the right side of the law" regarding the latest Medicaid rebate controversy, Gerberry believes investors should consider the risk of a future settlement related to the issue. He cut his price target on Mylan shares to $45 from $55, but keeps an Outperform rating on the stock as he sees cash flows being sufficient to justify the current price.
09/23/16
BERN
09/23/16
NO CHANGE
BERN
Mylan generic Epipen to lower EPS by about 10%, says Bernstein
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
09/22/16
ARGS
09/22/16
NO CHANGE
ARGS
Mylan weakness creates good entry point, says Argus
After Mylan's stock fell 17% over the last month, Argus analyst Jacob Kilstein thinks that the stock has reached an attractive entry point, He says that the company's new generic EpiPen will cannibalize branded sales but should help it beat upcoming generic competitors. He thinks that the stock is undervalued and keeps a Buy rating on the stock.
09/22/16
LEER
09/22/16
NO CHANGE
LEER
Outperform
No tangible outcomes likely to result from Mylan EpiPen hearing, says Leerink
Leerink analyst Jason Gerberry believes no tangible outcomes are likely to result from the House Committee Hearing on Mylan's EpiPen. Nonetheless, the analyst highlights that CEO Heather Bresch stated at the hearing that the company has invested in a new formulation of EpiPen, with a 24-month shelf life versus the current 12-month. Gerberry believes this is a relatively modest benefit and says he is skeptical the line extension will be able to preserve meaningful share if/when an AB-rated generic gets approved. The analyst reiterates an Outperform rating on the shares.
NVS Novartis
$78.96

-0.29 (-0.37%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.
PFE Pfizer
$33.87

0.55 (1.65%)

08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
PHG Philips
$29.59

0.21 (0.71%)

08/23/16
JEFF
08/23/16
DOWNGRADE
Target $58
JEFF
Underperform
ResMed cut to Underperform at Jefferies as peer seen closing gap
As previously reported, Jefferies analyst Anthony Petrone downgraded ResMed (RMD) to Underperform from Hold, noting that the firm's survey and expert calls indicate that those in the field see the company's AirSense10 as still "best-in-class," but Philips' (PHG) Dream has closed the gap while being priced at a discount. Lower Medicare rates that just became effective are pressuring private rates and are seen leading to further consolidation and price pressure, the analyst added. Petrone cut his price target on ResMed shares to $58 from $60.
08/10/16
08/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from Neutral at Macquarie with analyst Tim Nollen saying he thinks Disney owning this technology gives it commanding position on future content viewership as Bam Tech is a premier OTT streaming technology, allowing Disney to connect directly with consumers. 2. Coach (COH) upgraded to Neutral from Underperform at BofA/Merrill with analyst Lorraine Hutchinson saying management guided margins to 18.5-19%, in line with her 18.5% estimate, reflecting a strategic reduction in the wholesale business, thinks more realistic EBIT targets indicates management has de-risked its outlook, and expects consensus estimates to move towards hers. 3. Philips (PHG) upgraded to Buy from Neutral at UBS with the firm citing management's targets for margin growth, improved momentum in two key divisions, and the company's position in businesses that are likely to benefit from the secular shift toward value based care. 4. Yelp (YELP) upgraded to Outperform from Market Perform at Raymond James, to Neutral from Underperform at BofA/Merrill, to Buy from Hold at Axiom, and to Buy from Neutral at Mizuho. 5. General Dynamics (GD) upgraded to Outperform from Market Perform at Bernstein with Douglas Harned saying shares of General Dynamics are valued at a larger discount to other prime contractors than it has been in the last 14 years and overly discounts weakness in the large cabin business jet market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/16
UBSW
08/10/16
UPGRADE
UBSW
Buy
Philips upgraded to Buy at UBS
As reported previously, UBS raised Phillips to Buy from Neutral. The firm sees reason for optimism for investors, citing management's targets for margin growth, improved momentum in two key divisions, and the company's position in businesses that are likely to benefit from the secular shift toward value based care.
08/10/16
UBSW
08/10/16
UPGRADE
UBSW
Buy
Philips upgraded to Buy from Neutral at UBS
REGN Regeneron
$402.02

-4.34 (-1.07%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
08/05/16
BARD
08/05/16
DOWNGRADE
Target $448
BARD
Neutral
Regeneron downgraded to Neutral at Baird
As reported previously, Baird downgraded Regeneron to Neutral from Outperform. The firm sees risk that the company will not be able to beat earnings consensus over the 2017/18 time frame unless there is a 15-20% downward revision in consensus estimates. Baird lowered its price target to $448 from $505 on Regeneron shares.
08/05/16
LEER
08/05/16
NO CHANGE
Target $511
LEER
Outperform
Regeneron price target lowered to $511 from $530 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron to $511 from $530, citing cautious guidance following the company's Q2 results. Nonetheless, the analyst points out its Eylea "solid" sales, beating by 2% in the U.S. and 5% overall. The analyst remains positive about Regeneron's product portfolio, strategy, management, and long-term potential. He reiterates an Outperform rating on the shares.
RNR RenaissanceRe
$120.16

-0.02 (-0.02%)

12/07/15
NOMU
12/07/15
UPGRADE
NOMU
Neutral
RenaissanceRe upgraded to Neutral from Reduce at Nomura
12/07/15
12/07/15
UPGRADE

On the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Abbott (ABT) upgraded to Buy from Hold at Jefferies...Altisource (ASPS) upgraded to Neutral from Sell at Compass Point...American Electric (AEP) upgraded to Buy from Neutral at UBS...BB&T (BBT) upgraded to Strong Buy from Outperform at Raymond James...Eli Lilly (LLY) upgraded to Buy from Hold at Deutsche Bank...Extra Space Storage (EXR) upgraded to Overweight from Sector Weight at KeyBanc...Isle of Capri (ISLE) upgraded to Buy from Hold at Stifel...Kroger (KR) upgraded to Buy from Neutral at Northcoast...Laredo Petroleum (LPI) upgraded to Hold from Reduce at KLR Group...Medley Capital (MCC) upgraded to Outperform from Market Perform at Wells Fargo...Norfolk Southern (NSC) upgraded to Equal Weight from Underweight at Barclays...Public Storage (PSA) upgraded to Sector Weight from Underweight at KeyBanc...RenaissanceRe (RNR) upgraded to Neutral from Reduce at Nomura...TransCanada (TRP) upgraded to Outperformer from Sector Performer at CIBC.
04/28/16
SBSH
04/28/16
DOWNGRADE
Target $122
SBSH
Neutral
RenaissanceRe downgraded to Neutral from Buy at Citi
Citi analyst Todd Bault downgraded RenaissanceRe to Neutral saying the company's Q1 results "displayed large negative volatility." The analyst cut his price target for the shares to $122 from $138.
07/11/16
KBWI
07/11/16
DOWNGRADE
KBWI
Market Perform
RenaissanceRe downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette downgraded RenaissanceRe to Market Perform after assuming coverage of the name. The firm cites lowered return on equity expectations and interest rate pressures for the rating change.
SNY Sanofi
$38.19

0.36 (0.95%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Sanofi initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Sanofi with a Neutral rating and EUR 76 price target.
09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Neutral
Sanofi upgraded to Neutral from Underperform at Exane BNP Paribas
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/08/16
09/08/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Overweight from Neutral at JPMorgan with analyst Chris Schott saying new products could drive upside to 2017 estimates while the risk/reward is favorable into solanezumab data late this year. 2. Johnson Controls (JCI) upgraded to Outperform from Neutral at Macquarie with analyst Mike Wood saying he has increased confidence on the commercial recovery, upside to Tyco synergies, improving cash flow, and potential for further portfolio simplification. 3. Sanofi (SNY) upgraded to Buy from Hold at Berenberg. 4. VMware (VMW) reinstated with Overweight from Neutral at JPMorgan with analyst Mark Murphy saying partner interviews highlight strength in the company's products and Dell has publicly stated that its global distribution network can lead to $1B of incremental VMware revenue. 5. Volaris (VLRS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ZLTQ ZELTIQ
$39.22

0.85 (2.22%)

06/27/16
PIPR
06/27/16
NO CHANGE
Target $40
PIPR
Overweight
ZELTIQ able to recognize some CoolAdvantage revenue in Q2, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien noted that the timing of the commercial launch of the new CoolAdvantage applicator from Zeltiq, while late in the quarter, will allow the company to recognize some CoolAdvantage revenue in Q2, which is important given concerns it was going to get pushed out. The analyst, who said the applicators carry multiple benefits for both the patient and physician, keeps an Overweight rating and $40 price target on ZELTIQ shares.
08/09/16
BMUR
08/09/16
NO CHANGE
Target $39
BMUR
Buy
ZELTIQ price target raised to $39 from $35 at Brean Capital
Brean Capital raised its price target on ZELTIQ to $39 from $35 following impressive Q2 results. The firm cited the company's improved revenue momentum and its entry into the Chinese market, which should lead to stronger international revenue growth. Brean Capital reiterated its Buy rating on ZELTIQ shares.
08/24/16
LEER
08/24/16
NO CHANGE
Target $48
LEER
Outperform
ZELTIQ remains a top small cap pick, says Leerink
Leerink analyst Richard Newitter says ZELTIQ remains a top small cap pick as he continues to see numerous drivers of both increased CoolSculpting system adoption and per system utilization. The analyst also continues to have confidence in the company's profitability ramp trajectory. Newitter reiterates an Outperform rating and $48 price target on the shares.
09/21/16
STFL
09/21/16
NO CHANGE
STFL
ZELTIQ price target raised to $52 from $38 at Stifel
Stifel analyst Jonathan Block says that Zeltiq will have several gross margin tailwinds in 2017. He expects the company's gross margins to rise by about four percentage points next year, and he keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

CNX

CONSOL

$21.30

-0.48 (-2.20%)

, CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

15:02
12/10/16
12/10
15:02
12/10/16
15:02
Conference/Events
CONE Midstream participates in an analyst and investor day »

Management participates…

CNX

CONSOL

$21.30

-0.48 (-2.20%)

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

, CNX

CONSOL

$21.30

-0.48 (-2.20%)

14:59
12/10/16
12/10
14:59
12/10/16
14:59
Conference/Events
CONSOL to host analyst and investor day »

Analyst and Investor Day…

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

CNX

CONSOL

$21.30

-0.48 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BG

Bunge

$73.36

-0.04 (-0.05%)

14:54
12/10/16
12/10
14:54
12/10/16
14:54
Conference/Events
Bunge to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

14:50
12/10/16
12/10
14:50
12/10/16
14:50
Conference/Events
AMD to host Summit Ridge a "Zen"-based CPU at New Horizon »

President & CEO Su…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$50.76

0.61 (1.22%)

14:41
12/10/16
12/10
14:41
12/10/16
14:41
Conference/Events
Arthur J. Gallagher to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NYT

New York Times

$14.10

0.15 (1.08%)

14:34
12/10/16
12/10
14:34
12/10/16
14:34
Conference/Events
Detroit Economic Club to hold a luncheon meeting »

Mark Thompson, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$27.16

0.89 (3.39%)

14:28
12/10/16
12/10
14:28
12/10/16
14:28
Conference/Events
AstraZeneca has a luncheon meeting with Philadelphia Securities Association »

Luncheon Meeting being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Feb

CASC

Cascadian Therapeutics

$5.65

-0.03 (-0.53%)

, GHDX

Genomic Health

$30.81

-0.17 (-0.55%)

04:55
12/10/16
12/10
04:55
12/10/16
04:55
Conference/Events
UT Health Science Center to hold a symposium »

2016 San Antonio Breast…

CASC

Cascadian Therapeutics

$5.65

-0.03 (-0.53%)

GHDX

Genomic Health

$30.81

-0.17 (-0.55%)

MYGN

Myriad Genetics

$17.40

0.41 (2.41%)

RDUS

Radius Health

$43.94

-3.13 (-6.65%)

OCX

OncoCyte

$6.15

0.05 (0.82%)

ABBV

AbbVie

$61.54

0.64 (1.05%)

BAYRY

Bayer

$100.04

1.14 (1.15%)

CELG

Celgene

$113.47

0.41 (0.36%)

CLDX

Celldex

$3.75

0.01 (0.27%)

DNA

Bought by RHHBY

HRTX

Heron Therapeutics

$14.90

-0.55 (-3.56%)

PFE

Pfizer

$31.70

0.76 (2.46%)

PBYI

Puma Biotechnology

$36.50

0.05 (0.14%)

TSRO

TESARO

$129.97

-1.57 (-1.19%)

NSTG

NanoString

$21.79

-0.35 (-1.58%)

NVS

Novartis

$69.74

2.15 (3.18%)

NVTA

Invitae

$7.24

0.28 (4.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 11

    Jan

BBSI

Barrett Business

$62.30

1.85 (3.06%)

, BREW

Craft Brew

$16.65

0.45 (2.78%)

04:55
12/10/16
12/10
04:55
12/10/16
04:55
Conference/Events
Roth Capital to hold a conference »

5th Annual ROTH Utah…

BBSI

Barrett Business

$62.30

1.85 (3.06%)

BREW

Craft Brew

$16.65

0.45 (2.78%)

CHKE

Cherokee

$11.10

-0.35 (-3.06%)

DFBG

Differential Brands

$3.20

0.25 (8.47%)

DLA

Delta Apparel

$20.77

-0.39 (-1.84%)

ESCA

Escalade

$13.65

-0.15 (-1.09%)

FLKS

Flex Pharma

$6.29

-0.01 (-0.16%)

KONA

Kona Grill

$12.75

0.05 (0.39%)

LNDC

Landec

$15.05

-0.25 (-1.63%)

MEET

MeetMe

$5.63

0.16 (2.93%)

MITK

Mitek Systems

$6.50

0.35 (5.69%)

MB

MINDBODY

$20.70

-0.25 (-1.19%)

OSIS

OSI Systems

$78.17

1.22 (1.59%)

PLNT

Planet Fitness

$21.01

-0.07 (-0.33%)

ROX

Castle Brands

$0.75

0.0309 (4.30%)

PRTS

U.S. Auto Parts

$3.33

0.09 (2.78%)

RSYS

RadiSys

$4.77

0.11 (2.36%)

SWHC

Smith & Wesson

$21.07

-0.16 (-0.75%)

VSTO

Vista Outdoor

$38.62

-1.24 (-3.11%)

WMAR

West Marine

$9.41

0.13 (1.40%)

ZAGG

ZAGG

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 09

    Jan

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.